This Is Too Hot For Arcutis Biotherapeutics Inc (NASDAQ: ARQT), Let’s Take A Closer Look

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Yahoo Finance discussed the stock recently as it posted Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Stocks Info

Arcutis Biotherapeutics Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Arcutis Biotherapeutics Inc is $1.08B. A total of 2.02 million shares were traded on the day, compared to an average of 5.14M shares.

In the most recent transaction, Heron Patrick J bought 21,052 shares of ARQT for 9.50 per share on Mar 04 ’24. After the transaction, the Director now owns 8,785,284 company shares. In a previous transaction on Mar 04 ’24, Watanabe Todd Franklin sold 14,903 shares at 11.12 per share. ARQT shares that the insider owns now total 874,533.

Among the insiders who sold shares, Burnett Patrick disposed of 4,782 shares on Mar 04 ’24 at a per-share price of $11.12. This resulted in the insider holding 269,300 shares of ARQT after the transaction. In another insider transaction, Matsuda Masaru sold 3,760 shares at $11.12 per share on Mar 04 ’24. Company shares held by the See Remark now total 190,424.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, ARQT has a high of $15.40 and a low of $1.76.

As of this writing, ARQT has an earnings estimate of -$0.74 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.65 per share and a lower estimate of -$0.91. The company reported an EPS of -$0.73 in the last quarter, which was 15.10% higher than expectations of -$0.86.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ARQT is Buy with a score of 4.50.

Most Popular

Related Posts